{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-012652","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.696811+00:00","generated_at":"2026-06-25T23:19:20.324860+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corcept Q1 revenue $93.7M (+18% YoY); reiterates FY2022 guidance $400-430M","bullets":["Diluted EPS $0.20 vs $0.18 YoY; cash & investments $368.1M (up $32.3M in Q1).","Phase 3 trial of relacorilant in platinum-resistant ovarian cancer to start this quarter.","GRATITUDE I/II data for miricorilant in antipsychotic weight gain expected Q4 2022.","Relacorilant NDA for Cushing's syndrome now expected H2 2023 (pandemic delays).","Operating expenses $66.9M (+12% YoY) on expanded R&D and legal costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-012652","json":"https://secwatch.observer/filing/0001628280-22-012652.json","markdown":"https://secwatch.observer/filing/0001628280-22-012652.md","text":"https://secwatch.observer/filing/0001628280-22-012652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022012652/0001628280-22-012652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022012652/cort-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:19:20.324860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}